Compare JetBlue Airways Corporation (JBLU) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JetBlue Airways Corporation vs Novavax Inc — how do they compare? JetBlue Airways Corporation trades at $3.84 (market cap $1.48B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: Novavax Inc is the larger of the two by market cap, and Novavax Inc is trading nearer its 52-week high, JetBlue Airways Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JetBlue Airways Corporation for 44 Days and Novavax Inc for 59 Days on average.
| JBLU | NVAX | |
|---|---|---|
Market Cap | $1.48B | $1.82B |
Volume | 30,275,693 | 6,198,505 |
Sector | Industrials | Health |
52-Week High | $6.46 | $12.75 |
52-Week Low | $3.84 | $6.22 |
Typical Hold Time | 44 Days | 59 Days |
Enterprise Value | $8.84B | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JetBlue (JBLU) trades at $3.92, down 1.26% today, reflecting ongoing operational challenges. The airline faces persistent profitability issues with a net income margin of -9.32% and negative ROE of -44.36%. Recent Q2 2026 earnings beat expectations but followed two consecutive misses. Technical indicators show bearish momentum with the stock trading near key support levels. The company continues expansion efforts with new Colombia routes while grappling with high fuel costs and capacity constraints.
Investment outlook remains cautious given sustained losses and high debt levels. The consensus price target of $5.89 offers 50% upside potential, but execution risks from fuel price volatility and competitive pressures persist. Analyst sentiment leans neutral with 62% hold ratings, suggesting limited near-term catalysts for significant price appreciation despite attractive valuation multiples.
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and a strong buy consensus from analysts (73.9% buy ratings). The company reported a net income of $440.3M in 2025, a significant turnaround from prior losses, though 2026 projections show a return to negative margins. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: near-term catalysts include partnership-driven growth and vaccine approvals, but persistent cash burn and projected 2026 losses pose risks. Investor sentiment is buoyed by recent earnings beats and strategic shifts, yet execution on profitability remains critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
